Pharmosa Biopharm Inc. (TPEX:6875)
Taiwan
· Delayed Price · Currency is TWD 47.30
+0.30 (0.64%)
Apr 24, 2025, 1:20 PM CST
Pharmosa Biopharm Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Net Income | -166.65 | 8.46 | -266.51 | -256.48 | -181.7 | Upgrade
|
| Depreciation & Amortization | 25.81 | 23.32 | 12.7 | 11.79 | 10.62 | Upgrade
|
| Other Amortization | - | - | - | 0.01 | - | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.34 | - | - | - | - | Upgrade
|
| Loss (Gain) on Equity Investments | -1.95 | -5.5 | -3.93 | -0.66 | -4.63 | Upgrade
|
| Stock-Based Compensation | 3.58 | 0.87 | 0.59 | 15.04 | 4 | Upgrade
|
| Other Operating Activities | -7.73 | - | -0.02 | -0.02 | - | Upgrade
|
| Change in Accounts Receivable | -3.37 | -1.18 | 0.03 | -0.14 | -0.15 | Upgrade
|
| Change in Inventory | -2.83 | -21.91 | - | - | - | Upgrade
|
| Change in Accounts Payable | 0.09 | 0.59 | - | 2 | -0.77 | Upgrade
|
| Change in Unearned Revenue | 11.71 | - | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | 13.84 | 26.81 | -1.19 | -9.05 | -8.83 | Upgrade
|
| Operating Cash Flow | -127.16 | 31.45 | -258.31 | -237.51 | -181.45 | Upgrade
|
| Capital Expenditures | -165.27 | -81.46 | -10.16 | -3.06 | -7.05 | Upgrade
|
| Sale (Purchase) of Intangibles | -0.7 | -0.01 | -0.03 | -0.19 | - | Upgrade
|
| Investment in Securities | -869 | - | - | - | - | Upgrade
|
| Other Investing Activities | -4.6 | -1.4 | 0.02 | 8 | 1.99 | Upgrade
|
| Investing Cash Flow | -1,040 | -82.87 | -10.17 | 4.75 | -5.07 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 161 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 9.5 | Upgrade
|
| Total Debt Issued | - | - | - | - | 170.5 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -61 | -165 | Upgrade
|
| Long-Term Debt Repaid | -21.16 | -14.22 | -15.9 | -26.34 | -33.99 | Upgrade
|
| Total Debt Repaid | -21.16 | -14.22 | -15.9 | -87.34 | -198.99 | Upgrade
|
| Net Debt Issued (Repaid) | -21.16 | -14.22 | -15.9 | -87.34 | -28.48 | Upgrade
|
| Issuance of Common Stock | 963.26 | 367.18 | 495.42 | 367.02 | 637.29 | Upgrade
|
| Other Financing Activities | - | - | - | - | -12 | Upgrade
|
| Financing Cash Flow | 942.11 | 352.97 | 479.52 | 279.68 | 596.81 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.01 | 0 | 0.01 | - | - | Upgrade
|
| Net Cash Flow | -224.62 | 301.55 | 211.05 | 46.93 | 410.29 | Upgrade
|
| Free Cash Flow | -292.43 | -50.01 | -268.47 | -240.57 | -188.5 | Upgrade
|
| Free Cash Flow Margin | -174.51% | -15.90% | - | - | - | Upgrade
|
| Free Cash Flow Per Share | -2.31 | -0.44 | -2.73 | -2.83 | -3.96 | Upgrade
|
| Cash Interest Paid | 4.44 | 2.86 | 0.65 | 1.21 | 3.86 | Upgrade
|
| Cash Income Tax Paid | 2.94 | - | - | - | - | Upgrade
|
| Levered Free Cash Flow | -255.43 | -50.37 | -165.23 | -135.95 | -115.21 | Upgrade
|
| Unlevered Free Cash Flow | -253.92 | -48.59 | -164.83 | -135.19 | -112.79 | Upgrade
|
| Change in Net Working Capital | -19.27 | -10.46 | -1.78 | -3.17 | 3.23 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.